Clinical Trial Update: A Study of Deflazacort (Emflaza®) in Participants With Duchenne Muscular Dystrophy (DMD) [Phase 3]

View source ↗

Summary

A Phase 3 trial of deflazacort (Emflaza) in Duchenne Muscular Dystrophy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• EMFLAZA (deflazacort)

Snippet

Sponsor: PTC Therapeutics | Conditions: Duchenne Muscular Dystrophy | Phase 3 | Status: WITHDRAWN